Rapid Micro Biosystems Reports Q1 Results with Strong Revenue Growth, High Cash Burn, Reaffirms 2026 Guidance
RPID sits 23% above its 52-week low of $2.01.
Summary
Rapid Micro Biosystems announced Q1 2026 results showing revenue growth and reaffirmed 2026 guidance, but reported a substantial increase in net loss and a significant reduction in cash, raising critical liquidity concerns.
Key Events · Earnings and Guidance · RPID
-
Q1 2026 Revenue Growth
Total revenue increased 11.1% year-over-year to $8.0 million, with product revenue up 36% and recurring revenue up 28%.
-
Increased Net Loss
Net loss widened to $14.3 million ($0.31 per share) in Q1 2026, compared to $11.3 million ($0.26 per share) in Q1 2025.
-
Significant Cash Burn
Cash, cash equivalents, and short-term investments decreased by $15.35 million, from $38.6 million at year-end 2025 to $23 million as of March 31, 2026, indicating a rapid depletion of liquidity.
-
2026 Guidance Reaffirmed
The company reaffirmed its full-year 2026 revenue guidance of $37.0 million to $41.0 million and gross margin guidance of approximately 20%.
Analysis · RPID · Industrial Applications And Services
Rapid Micro Biosystems reported strong Q1 2026 revenue growth, driven by increased product sales and recurring revenue, and reaffirmed its full-year 2026 guidance. However, the company experienced a significant cash burn, with cash and equivalents dropping from $38.6 million to $23 million in one quarter. This rapid depletion of liquidity raises serious concerns about the company's cash runway, especially in light of the previously stated 12-month liquidity runway from the March 12, 2026 10-K filing. The net loss also widened.
At the time of this filing, RPID was trading at $2.48 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $113.5M. The 52-week trading range was $2.01 to $4.94. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.